Celgene wins Chinese regulatory OK for Revlimid
(Reuters) - Celgene Corp on Monday said its drug Revlimid won full regulatory approval in China for patients with relapsed or refractory multiple myeloma, a type of cancer that starts in the plasma cells in the bone marrow.
Multiple myeloma is the second most commonly diagnosed blood cancer. There are an estimated 750,000 people with the disease worldwide, according to the International Myeloma Foundation.
Celgene said it expects the drug to be available to Chinese patients late in the second quarter of 2013.
In addition, the biotechnology company said Revlimid, or lenalidomide, was granted priority review by the U.S. Food and Drug Administration as a treatment for patients with relapsed or refractory mantle cell lymphoma.
Revlimid is approved in combination with dexamethasone for the treatment of patients with multiple myeloma, who have received at least one prior therapy, in almost 70 countries, including the Americas and Europe.
It is also approved in the United States, Canada, Switzerland, Australia, New Zealand and several Latin American countries, as well as Malaysia and Israel, for transfusion-dependent anemia.
(Reporting By Debra Sherman; Editing by Gerald E. McCormick)
- Tweet this
- Share this
- Digg this
- In his native Alabama, Apple CEO's announcement he is gay prompts discomfort for some
- U.S. nurse defies Ebola quarantine with bike ride; negotiations fail
- Nurse defies Ebola quarantine with bike ride; negotiations fail |
- Islamic State fighters kill 220 Iraqis from tribe that opposed them
- PM Modi boots officials out of the first class cabin
A nurse who treated Ebola patients in Sierra Leone but has tested negative for the virus went for a bike ride, defying Maine's order that she be quarantined in her home and setting up a legal collision with Governor Paul LePage. Full Article
'Disastrous' health campaign feeds Pakistan's worrying polio spike. Full Article